Literature DB >> 30998826

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Henry T Quach1, Anna K Dewan2, Elizabeth J Davis3, Kristin K Ancell3, Run Fan4, Fei Ye4, Douglas B Johnson3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30998826      PMCID： PMC6567826          DOI： 10.1001/jamaoncol.2019.0046

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Immune Checkpoint Inhibitor Toxicity in 2018.

Authors:  Douglas B Johnson; Sunandana Chandra; Jeffrey A Sosman
Journal:  JAMA       Date:  2018-10-23       Impact factor: 56.272

2.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

Review 3.  Pruritus Associated with Targeted Anticancer Therapies and Their Management.

Authors:  Jennifer Wu; Mario E Lacouture
Journal:  Dermatol Clin       Date:  2018-07       Impact factor: 3.478

4.  High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.

Authors:  Alexander T Faje; Donald Lawrence; Keith Flaherty; Christine Freedman; Riley Fadden; Krista Rubin; Justine Cohen; Ryan J Sullivan
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

5.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

Authors:  Camille Hua; Lise Boussemart; Christine Mateus; Emilie Routier; Céline Boutros; Hugo Cazenave; Roxane Viollet; Marina Thomas; Séverine Roy; Naima Benannoune; Gorana Tomasic; Jean-Charles Soria; Stéphane Champiat; Matthieu Texier; Emilie Lanoy; Caroline Robert
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

6.  Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Mehdi Rashighi; Priti Agarwal; Madhuri Garg; Kingsley I Essien; Lila S Pell; John E Harris
Journal:  J Invest Dermatol       Date:  2018-11-10       Impact factor: 8.551
  6 in total
  27 in total

1.  The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.

Authors:  James Randall Patrinely; Anna K Dewan; Douglas B Johnson
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

2.  Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Kennedy Yao Yi Ng; Sze Huey Tan; Jack Jie En Tan; Desiree Shu Hui Tay; Ailica Wan Xin Lee; Andrea Jing Shi Ang; Lawrence Wen Jun Wong; Su Pin Choo; David Wai-Meng Tai; Joycelyn Jie Xin Lee
Journal:  Liver Cancer       Date:  2021-10-26       Impact factor: 11.740

3.  Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

Authors:  James R Patrinely; Laura X Baker; Elizabeth J Davis; Haocan Song; Fei Ye; Douglas B Johnson
Journal:  Cancer       Date:  2020-05-28       Impact factor: 6.860

Review 4.  Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.

Authors:  Brandon E Cohen; Prashiela Manga; Krysta Lin; Nada Elbuluk
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

5.  Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.

Authors:  Satya Das; Kristen K Ciombor; Sigurdis Haraldsdottir; Yoanna Pumpalova; Ibrahim H Sahin; G Pineda; Yu Shyr; E P Lin; Chih-Yuan Hsu; Shih-Kai Chu; Laura W Goff; Dana B Cardin; Mehmet A Bilen; George A Fisher; Christina Wu; Jordan Berlin
Journal:  Oncologist       Date:  2020-01-14

Review 6.  Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.

Authors:  Brendan L Mangan; Renee K McAlister; Justin M Balko; Douglas B Johnson; Javid J Moslehi; Andrew Gibson; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 4.335

Review 7.  Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.

Authors:  Annu Susan George; Cornelius J Fernandez; Dilip Eapen; Joseph M Pappachan
Journal:  touchREV Endocrinol       Date:  2021-04-28

8.  The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Saby George; Elizabeth J Bell; Ying Zheng; Ruth Kim; John White; Geeta Devgan; Jodi Smith; Lincy S Lal; Nicole M Engel-Nitz; Frank X Liu
Journal:  Oncologist       Date:  2021-05-29

9.  Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety.

Authors:  Caroline A Nebhan; Douglas B Johnson
Journal:  Expert Rev Anticancer Ther       Date:  2021-02-14       Impact factor: 3.627

Review 10.  Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.

Authors:  Eli P Darnell; Meghan J Mooradian; Erez N Baruch; Melis Yilmaz; Kerry L Reynolds
Journal:  Curr Oncol Rep       Date:  2020-03-21       Impact factor: 5.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.